209 related articles for article (PubMed ID: 32419831)
21. Evaluation of sulfated fungal beta-glucans from the sclerotium of Pleurotus tuber-regium as a potential water-soluble anti-viral agent.
Zhang M; Cheung PC; Ooi VE; Zhang L
Carbohydr Res; 2004 Sep; 339(13):2297-301. PubMed ID: 15337458
[TBL] [Abstract][Full Text] [Related]
22. Novel agents and strategies to treat herpes simplex virus infections.
Kleymann G
Expert Opin Investig Drugs; 2003 Feb; 12(2):165-83. PubMed ID: 12556212
[TBL] [Abstract][Full Text] [Related]
23. A new promising candidate to overcome drug resistant herpes simplex virus infections.
Zinser E; Krawczyk A; Mühl-Zürbes P; Aufderhorst U; Draßner C; Stich L; Zaja M; Strobl S; Steinkasserer A; Heilingloh CS
Antiviral Res; 2018 Jan; 149():202-210. PubMed ID: 29155164
[TBL] [Abstract][Full Text] [Related]
24. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.
Tyring SK; Baker D; Snowden W
J Infect Dis; 2002 Oct; 186 Suppl 1():S40-6. PubMed ID: 12353186
[TBL] [Abstract][Full Text] [Related]
25. Virucidal effect of peppermint oil on the enveloped viruses herpes simplex virus type 1 and type 2 in vitro.
Schuhmacher A; Reichling J; Schnitzler P
Phytomedicine; 2003; 10(6-7):504-10. PubMed ID: 13678235
[TBL] [Abstract][Full Text] [Related]
26. Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials.
Sarisky RT; Bacon TH; Boon RJ; Duffy KE; Esser KM; Leary J; Locke LA; Nguyen TT; Quail MR; Saltzman R
Arch Virol; 2003 Sep; 148(9):1757-69. PubMed ID: 14505088
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.
; Abu-Elyazeed RR; Heineman T; Dubin G; Fourneau M; Leroux-Roels I; Leroux-Roels G; Richardus JH; Ostergaard L; Diez-Domingo J; Poder A; Van Damme P; Romanowski B; Blatter M; Silfverdal SA; Berglund J; Josefsson A; Cunningham AL; Flodmark CE; Tragiannidis A; Dobson S; Olafsson J; Puig-Barbera J; Mendez M; Barton S; Bernstein D; Mares J; Ratner P
Vaccine; 2013 Dec; 31(51):6136-43. PubMed ID: 23850416
[TBL] [Abstract][Full Text] [Related]
28. Oral and perioral herpes simplex virus type 1 (HSV-1) infection: review of its management.
Arduino PG; Porter SR
Oral Dis; 2006 May; 12(3):254-70. PubMed ID: 16700734
[TBL] [Abstract][Full Text] [Related]
29. Valaciclovir: a review of its long term utility in the management of genital herpes simplex virus and cytomegalovirus infections.
Ormrod D; Scott LJ; Perry CM
Drugs; 2000 Apr; 59(4):839-63. PubMed ID: 10804039
[TBL] [Abstract][Full Text] [Related]
30. Herpes simplex virus infection.
Whitley RJ
Semin Pediatr Infect Dis; 2002 Jan; 13(1):6-11. PubMed ID: 12118847
[TBL] [Abstract][Full Text] [Related]
31. Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo.
Duan J; Liuzzi M; Paris W; Lambert M; Lawetz C; Moss N; Jaramillo J; Gauthier J; Déziel R; Cordingley MG
Antimicrob Agents Chemother; 1998 Jul; 42(7):1629-35. PubMed ID: 9660995
[TBL] [Abstract][Full Text] [Related]
32. The effect of gramicidin, a topical contraceptive and antimicrobial agent with anti-HIV activity, against herpes simplex viruses type 1 and 2 in vitro.
Bourinbaiar AS; Coleman CF
Arch Virol; 1997; 142(11):2225-35. PubMed ID: 9672588
[TBL] [Abstract][Full Text] [Related]
33. Antiviral activity of Australian tea tree oil and eucalyptus oil against herpes simplex virus in cell culture.
Schnitzler P; Schön K; Reichling J
Pharmazie; 2001 Apr; 56(4):343-7. PubMed ID: 11338678
[TBL] [Abstract][Full Text] [Related]
34. Reducing the risk of transmitting genital herpes: advances in understanding and therapy.
Leone P
Curr Med Res Opin; 2005 Oct; 21(10):1577-82. PubMed ID: 16238897
[TBL] [Abstract][Full Text] [Related]
35. [Prevention and therapy of herpesvirus infections].
Abb J
Zentralbl Bakteriol Mikrobiol Hyg B; 1985 Feb; 180(2-3):107-20. PubMed ID: 2986378
[TBL] [Abstract][Full Text] [Related]
36. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial.
Schacker T; Hu HL; Koelle DM; Zeh J; Saltzman R; Boon R; Shaughnessy M; Barnum G; Corey L
Ann Intern Med; 1998 Jan; 128(1):21-8. PubMed ID: 9424977
[TBL] [Abstract][Full Text] [Related]
37. Herpes simplex virus infections of the central nervous system: encephalitis and meningitis, including Mollaret's.
Tyler KL
Herpes; 2004 Jun; 11 Suppl 2():57A-64A. PubMed ID: 15319091
[TBL] [Abstract][Full Text] [Related]
38. [Herpes simplex virus infections].
Kunkel M; Gärtner L; Oberender H
Z Gesamte Inn Med; 1985 Apr; 40(7):189-93. PubMed ID: 4039869
[TBL] [Abstract][Full Text] [Related]
39. Population-based surveillance of neonatal herpes simplex virus infection in Australia, 1997-2011.
Jones CA; Raynes-Greenow C; Isaacs D;
Clin Infect Dis; 2014 Aug; 59(4):525-31. PubMed ID: 24846638
[TBL] [Abstract][Full Text] [Related]
40. Natural history of neonatal herpes simplex virus infections in the acyclovir era.
Kimberlin DW; Lin CY; Jacobs RF; Powell DA; Frenkel LM; Gruber WC; Rathore M; Bradley JS; Diaz PS; Kumar M; Arvin AM; Gutierrez K; Shelton M; Weiner LB; Sleasman JW; de Sierra TM; Soong SJ; Kiell J; Lakeman FD; Whitley RJ;
Pediatrics; 2001 Aug; 108(2):223-9. PubMed ID: 11483781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
